ArticleJournal for immunotherapy of cancer2025

INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering.

Nisha Holay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.